Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Signs In-Network Contracts With Anthem Blue Cross, Blue Shield Plans

NEW YORK (GenomeWeb) – Sequenom said today that it has secured in-network contracts with Blue Cross and Blue Shield of Georgia, as well as Anthem Blue Cross and Blue Shield plans for Indiana, Kentucky, Missouri, Ohio, Wisconsin, and Virginia.

The agreements provide in-network coverage for Sequenom's noninvasive prenatal tests for high-risk and average-risk pregnancies. The Georgia agreement does not include HMO plans and the Virginia agreement does not include HealthKeepers products.

"Becoming an in-network provider with leading health insurers, particularly for average-risk pregnancies, is a critical component of our commercialization plan," Sequenom CEO and President Dirk van den Boom said in a statement.

The molecular diagnostic company originally inked a five-year agreement with the Blue Cross Blue Shield Association in 2013 to offer its testing services to the independent companies. However, the firm still had to negotiate in-network status with each of the 36 independent providers within the association.

In March, it signed agreements with Anthem Blue Cross and Blue Shield in Connecticut, Maine, and New Hampshire to provide coverage for NIPT for both high- and average-risk pregnancies.

The Scan

Time to Act

A new report urges the UK to consider regulations to protect against the misuse of genomic technologies, according to the Guardian.

Fulgent Seeking Defamation Suit

Fulgent Genetics says it plans to sue Los Angeles County Sheriff Alex Villanueva for defamation, the Los Angeles Times reports.

Speeding Gene-Edited Crops

Reuters reports that China's new trial rules will make it easier to grow gene-edited crops there.

Nucleic Acids Research Papers on Viral Recombination, Pan-Cancer Mutations, SARS-CoV-2 Variability

In Nucleic Acids Research this week: updated pipeline to detect viral recombination, mutational patterns in tumor samples, and more.